Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK4 | Q13043 | 13/20 | 1.00 |
| ▸ | STK3 | Q13188 | 5/20 | 1.00 |
| ▸ | AURKA | O14965 | 4/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 4/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 4/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 3/20 | 1.00 |
| ▸ | PIP5K1C | O60331 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 1.00 |
| ▸ | RIPK4 | P57078 | 1/20 | 1.00 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 1.00 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 1.00 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 1.00 |
| ▸ | MAP3K3 | Q99759 | 1/20 | 1.00 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 1.00 |
| ▸ | STK26 | Q9P289 | 1/20 | 1.00 |
| ▸ | TAOK2 | Q9UL54 | 1/20 | 1.00 |
| ▸ | MAP3K2 | Q9Y2U5 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366935 | 1.00 | STK4 (1.00) | STK4STK3AURKAPIK3CGAURKB | |
| SCHEMBL20628565 | 0.91 | STK3 (1.00) | STK4STK3AURKAPIK3CGAURKB | |
| SCHEMBL20628572 | 0.89 | PIK3CG (0.79) | STK4STK3AURKAPIK3CGAURKB | |
| SCHEMBL20628500 | 0.88 | PIK3CG (0.78) | STK4STK3AURKAPIK3CGAURKB | |
| SCHEMBL20628544 | 0.87 | STK3 (0.81) | STK4STK3AURKAPIK3CGAURKB | |
| SCHEMBL20628488 | 0.86 | STK3 (0.79) | STK4STK3AURKAPIK3CGAURKB | |
| SCHEMBL21938546 | 0.86 | STK3 (0.76) | STK4STK3AURKAPIK3CGAURKB | |
| SCHEMBL20628550 | 0.85 | STK3 (0.77) | STK4STK3AURKAPIK3CGAURKB | |
| SCHEMBL23219348 | 0.85 | STK3 (0.77) | STK4STK3AURKAPIK3CGAURKB | |
| SCHEMBL20628393 | 0.85 | STK3 (0.75) | STK4STK3AURKAPIK3CGAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325551-A1 | GASOTRANSMITTER METABOLITES AND ALZHEIMER'S DISEASE | UNIV LOUISIANA STATE (US) | 2025-10-23 | — | — | US | claimed |
| US-12280058-B2 | Gasotransmitter metabolites and Alzheimer's disease | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2025-04-22 | — | — | US | claimed |
| US-20210285938-A1 | GASOTRANSMITTER METABOLITES AND ALZHEIMER'S DISEASE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2021-09-16 | — | — | US | claimed |
| US-20260021108-A1 | USE OF INHIBITORS OF THE HIPPO SIGNALLING PATHWAY FOR THE TREATMENT OF CHRONIC NEPHROPATHIES | INST NAT SANTE RECH MED (FR) | 2026-01-22 | — | — | US | disclosed |
| US-20250325551-A1 | GASOTRANSMITTER METABOLITES AND ALZHEIMER'S DISEASE | UNIV LOUISIANA STATE (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4598540-A1 | USE OF INHIBITORS OF THE HIPPO SIGNALLING PATHWAY FOR THE TREATMENT OF CHRONIC NEPHROPATHIES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-08-13 | — | — | EP | disclosed |
| US-12280058-B2 | Gasotransmitter metabolites and Alzheimer's disease | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2024074461-A1 | USE OF INHIBITORS OF THE HIPPO SIGNALLING PATHWAY FOR THE TREATMENT OF CHRONIC NEPHROPATHIES | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-04-11 | — | — | WO | disclosed |
| US-20240082158-A1 | COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-03-14 | — | — | US | disclosed |
| EP-3713569-B1 | THERAPEUTIC PARTICLE COMPRISING A YAP1/WWRT1 INHIBITING AGENT AND THE GLUTAMINASE INHIBITING AGENT 2-CYCLOPROPYL-N-[5-(4-{ [5-(2-PHENYLACETAMIDO)-1,3,4-THIADIAZOL-2-YL]AMINO}PIPERIDIN-1-YL)-1,3,4-THIADIAZOL-2-YL] ACETAMIDE AND USE THEREOF FOR TREATING A PULMONARY DISEASE | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | Anhui Newstar Pharmaceutical Development Co., Ltd. (CN) | 2022-09-08 | — | — | US | disclosed |
| US-20210285938-A1 | GASOTRANSMITTER METABOLITES AND ALZHEIMER'S DISEASE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2021-09-16 | — | — | US | disclosed |
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2021-04-13 | — | — | US | disclosed |
| EP-3713569-A1 | COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION | University of Pittsburgh- Of the Commonwealth System of Higher Education (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20200276125-A1 | COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-09-03 | — | — | US | disclosed |
| US-20200208128-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2020-07-02 | — | — | US | disclosed |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd . (CN) | 2020-04-16 | — | — | US | disclosed |
| WO-2019104038-A1 | COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019006512-A1 | CARDIOMYOCYTE REGENERATION | THE UNIVERSITY OF QUEENSLAND (AU) | 2019-01-10 | — | — | WO | disclosed |
| EP-3424929-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd (CN) | 2019-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | MST1, STK11, MSTN | STK4 15/4885STK3 14/4885AURKA 950/4885 |
| US-20200208128-A1 | METHODS OF TREATING LIVER DISEASES | LIPC, PNPLA2, PNLIP | STK4 3670/4885STK3 2468/4885AURKA 4850/4885 |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | MST1, STK11, MSTN | STK4 15/4885STK3 14/4885AURKA 950/4885 |
| US-20260021108-A1 | USE OF INHIBITORS OF THE HIPPO SIGNALLING PATHWAY FOR THE TREATMENT OF CHRONIC NEPHROPATHIES | MST1, LATS1, LATS2 | STK4 18/4885STK3 12/4885AURKA 1793/4885 |
| US-20200276125-A1 | COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION | GLS2, GLS, YAP1 | STK4 384/4885STK3 230/4885AURKA 2480/4885 |
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | MST1, MSTN, MST1R | STK4 11/4885STK3 9/4885AURKA 2929/4885 |
| US-20240082158-A1 | COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION | GLS2, GLS, YAP1 | STK4 384/4885STK3 230/4885AURKA 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.